Resitu: minimally invasive surgical technology

Addressing breast cancer management

Breast cancer is the world’s most prevalent cancer form. In 2020, almost eight million women had been living with breast cancer for the past five years, 2.3 million were diagnosed with breast cancer and the disease caused a staggering 685,000 deaths. Ref

The WHO’s Global Breast Cancer Initiative’s (GBCI) objective is to reduce the global breast cancer mortality rate by 2.5% per year. Ref

Breast cancer management

Any lesion detected in mammography screening needs to be investigated. Today, a biopsy is taken and, if the lesion is cancerous, it is removed using open surgery.

The Resitu technology aims at removing the complete lesion already in the biopsy step, shortening the process by removing the need for open surgery.

Consultant Breast surgeon Andreas Karakatsanis at Uppsala University Hospital, Sweden:

“We see a rising demand for minimally invasive biopsy methods that facilitate the retrieval of larger tissue samples. That will minimize false negative results and minimize the need for recalls and new biopsies.

The most important, however, is to fuse a diagnostic procedure with the removal of an intact lesion with high-quality margin assessment. This could yield the potential to change practice and help a large group of patients, not only with benign disease, but also with small cancers of the breast, to avoid surgery. That way, we could avoid overtreatment, enhance patient experience and mitigate burden for the healthcare system.”

Innovative solution for improved breast biopsy

Resitu Medical is developing a minimally invasive, single-use, ultrasound guided device that uses diathermy to extract intact tissue sample with minimal bleeding.

Biopsy device for breast lesions

Resitu's first product in development is an electrosurgical instrument intended to provide breast tissue samples for diagnostic analysis of imaged abnormalities.